NCT06414434 - BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2027

Conditions

LiposarcomaRecurrent LiposarcomaMetastatic LiposarcomaUnresectable LiposarcomaMDM2 Gene AmplificationMyxoid LiposarcomaCIC-Rearranged Sarcoma

Interventions

DRUG

BTX-A51

Multi-kinase inhibitor, 1.0 mg, 2.0 mg, and 7.0 mg immediate-release capsules, taken orally per protocol.

Trial Locations (2)

RECRUITING

Brigham and Women's Hospital, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston